Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema

Next Previous
X
Search
Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Garadacimab (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms VANGUARD
  • Sponsors CSL; CSL Behring

    • Most Recent Events

    • 26 Feb 2024 Second Interim results assessing safety and efficacy of garadacimab in patients with hereditary angioedema From the Phase 3 (VANGUARD) study and open-label extension presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 14 Dec 2023 According to a CSL media release, the European Medicines Agency (EMA) has accepted the submission for Marketing Authorization Application (MAA) for garadacimab, based on data from this trial.
    • 14 Dec 2023 According to a CSL media release, the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema (HAE), based on data from this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top